Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 May;25(3):e70032.
doi: 10.1111/psyg.70032.

C-reactive protein-mediated dementia

Jia-Ming Tang  1 , Qing Lu  1 , Han-Xiao Lin  2 , Jia-Qi Li  2 , Xi-Chen Zhu  1   2 , Tao Ma  1   2
Affiliations
Review

C-reactive protein-mediated dementia

Jia-Ming Tang et al. Psychogeriatrics. 2025 May.

Abstract

Loss of memory is the main feature of dementia, accompanied by personality changes. Alzheimer's disease (AD) is the most prevalent type of dementia globally and a major contributor to disability and mortality in older individuals. Most notably, the neurological damage caused by AD is irreversible, but the current market still lacks effective medications for the treatment of dementia. Numerous research studies have indicated that the inflammatory response is significantly involved in the development of cognitive impairment, and elevated C-reactive protein (CRP) levels in healthy people increases the likelihood of future AD. CRP is a nonspecific indicator of inflammation. In clinical practice, CRP has long been proven to be one of the risk factors and powerful predictors of neurodegenerative diseases. Given the accessibility and cost-effectiveness of CRP testing, it is reasonable to anticipate its utilisation for early screening and monitoring the progression of AD in the future. This review therefore focuses on the specific relationship between CRP and various types of dementia and explores how CRP contributes to cognitive impairment.

Keywords: Alzheimer's disease; C‐reactive protein; inflammatory; mild cognitive impairment.

PubMed Disclaimer

References

REFERENCES

    1. Huntley J, Liu KY, Costafreda SG et al. Dementia prevention, intervention, and care: 2024 report of the lancet standing commission. Lancet 2024; 404: 572–628. https://doi.org/10.1016/S0140-6736(24)01296-0.
    1. Hage FG, Szalai AJ. C‐reactive protein gene polymorphisms, C‐reactive protein blood levels, and cardiovascular disease risk. J Am Coll Cardiol 2007; 50: 1115–1122. https://doi.org/10.1016/j.jacc.2007.06.012.
    1. Pankow JS, Folsom AR, Cushman M et al. Familial and genetic determinants of systemic markers of inflammation: the NHLBI family heart study. Atherosclerosis 2001; 154: 681–689. https://doi.org/10.1016/s0021-9150(00)00586-4.
    1. Ashraf‐ganjouei A, Moradi K, Bagheri S, Aarabi MH. The association between systemic inflammation and cognitive performance in healthy adults. J Neuroimmunol 2020; 345: 577272. https://doi.org/10.1016/j.jneuroim.2020.577272.
    1. Chen J, Ragab AA, Doyle MF et al. Inflammatory protein associations with brain MRI measures: Framingham offspring cohort. Alzheimers Dement J Alzheimers Assoc 2024; 20: 7465–7478. https://doi.org/10.1002/alz.14147.